Live feed08:00:00·45dPRReleasevia QuantisnowAlumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual MeetingByQuantisnow·Wall Street's wire, on your screen.ALMS· Alumis Inc.Health Care
